SOBRsafe Inc. (NASDAQ: SOBR), a provider of next-generation alcohol detection technology, has entered into definitive agreements for the immediate exercise of certain outstanding warrants at a reduced exercise price of $1.05 per share. The transaction is expected to generate gross proceeds of approximately $3.1 million before fees and expenses, providing the company with additional capital to support its operations and strategic initiatives.
In connection with the warrant exercise, SOBRsafe will issue new unregistered Series E and Series F warrants to purchase an aggregate of 4.7 million shares. The offering is expected to close on or about July 16, 2026, with H.C. Wainwright & Co. serving as the exclusive placement agent. The net proceeds from the offering are designated for working capital and general corporate purposes, which may include advancing the company's transdermal alcohol detection technology and expanding its market presence.
SOBRsafe's technology detects alcohol presence through the skin in real time, eliminating the need for breath, blood, or urine samples. The company's platform is designed for passive, dignified screening and monitoring, catering to behavioral health, family law, consumer markets, and licensing and integration applications. The additional funding could accelerate product development and commercial deployment.
The capital raise comes at a critical time as SOBRsafe seeks to scale its operations and capture market share in the growing alcohol monitoring industry. By reducing the warrant exercise price, the company incentivized warrant holders to provide immediate capital, strengthening its balance sheet. The transaction also reflects investor confidence in SOBRsafe's long-term prospects.
For more details, the full press release is available at https://nnw.fm/jzJjF. Additional information about SOBRsafe can be found at www.sobrsafe.com.
